A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Latest Information Update: 10 Jun 2025
At a glance
- Drugs Dual CLL1 CD38 targeting CAR T cell therapy Gracell Biotechnology (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
Most Recent Events
- 03 Jun 2025 Status changed from not yet recruiting to recruiting.
- 21 Mar 2025 New trial record